Employing the well-established EAE model of MS, we investigated the impact of MDL 72527, a pharmacological inhibitor of the SMOX pathway, on EAE-induced neurodegeneration and optic nerve inflammation. This evidence concerns the gene SMOX and myeloid sarcoma.